You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tyrosine Protein Kinase Inhibitors

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

Recurrent Non-Small Cell Lung Carcinoma, Stage IV NSCLC Trial in United States (Laboratory Biomarker Analysis, Paclitaxel

Completed
Has Results
  • Recurrent Non-Small Cell Lung Carcinoma
  • Stage IV Non-Small Cell Lung Cancer
  • Laboratory Biomarker Analysis
  • Paclitaxel Albumin-Stabilized Nanoparticle Formulation
  • Anchorage, Alaska
  • +11 more
Jun 26, 2021

TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy

Recruiting
  • Chronic Myeloid Leukemia
  • Pisa, Italy
  • +1 more
Jan 4, 2022

Called ROCURS, to Learn About COVID-19 Related Outcomes in

Active, not recruiting
  • Malignant Solid Tumors
  • +2 more
  • Whippany, New Jersey
    Bayer
Feb 2, 2023

METAstatic Gastrointestinal Stromal Tumors (METAGIST)

Recruiting
  • Gastro Intestinal Stromal Tumor
  • oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations
  • Bordeaux, France
    Institut Bergonié, Comprehensive Cancer Center
Dec 1, 2022

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

Recruiting
  • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Non Small Cell Lung Cancer, CNS Progression Trial in Aurora (Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • CNS Progression
  • Temozolomide plus Osimertinib
  • Temozolomide plus Lorlatinib
  • Aurora, Colorado
    University of Colorado Hospital
May 12, 2022

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

Completed
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Sep 23, 2021

Lung Cancer, Lung Adenocarcinoma, EGFR Activating Mutation Trial in Vandoeuvre-lès-Nancy (Collection of surgical waste)

Enrolling by invitation
  • Lung Cancer
  • +4 more
  • Collection of surgical waste
  • Vandoeuvre-lès-Nancy, Lorraine, France
    Seitlinger
Nov 24, 2021

Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug Trial in Czechia (Imatinib withdrawal, Dasatinib, Nilotinib)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Withdrawal;Drug
  • Imatinib withdrawal
  • +2 more
  • Brno, Czechia
  • +7 more
Aug 24, 2022

Safety of ICIs and TKIs Therapy for HCC

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Lenvatinib Oral Product
  • +2 more
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Jun 11, 2022

MEOI and HRQoL in CLL Patients Treated With BTKis

Recruiting
  • Chronic Lymphocytic Leukemia
    • Fountain Valley, California
    • +15 more
    Jan 16, 2023

    sFlt- 1, PIGF, and Niacin Levels in Premature Ovarian

    Completed
    • Premature Ovarian Insufficiency
    • ultrasound assessment
    • Gaziantep, Turkey
      Cengiz Gokcek Women's and Child's hospital
    Aug 30, 2021

    Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and

    Completed
    • Leukemia
    • No Intervention
    • Cambridge, Massachusetts
      Takeda
    Feb 28, 2023

    B-cell Malignancy, Low-grade, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma Trial in China (BGB-16673)

    Recruiting
    • B-cell Malignancy, Low-grade
    • +4 more
    • Beijing, Beijing, China
    • +8 more
    Jul 20, 2022

    Ovarian Reserve and Fertility in Chronic Myeloid Leukemia or

    Recruiting
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +2 more
    • Cytology Specimen Collection Procedure
    • +3 more
    • Los Angeles, California
      USC / Norris Comprehensive Cancer Center
    Nov 16, 2021

    Withdrawal of Second-generation Tyrosine Kinase Inhibitors After

    Recruiting
    • MMR on 12 Month
    • Guangzhou, Guangdong, China
    • +1 more
    Apr 21, 2022

    Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)

    Recruiting
    • Neoplasms
    • +12 more
    • Nanjing, Jiangsu, China
      Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
    Oct 28, 2023

    Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

    Recruiting
    • Liver Neoplasms
    • Tislelizumab plus tyrosine kinase inhibitor
    • Beijing, Beijing, China
      302 Hospital
    Sep 22, 2023

    Advanced NSCLC With MET Mutations Trial in United States (Tepotinib)

    Recruiting
    • Advanced Non-Small Cell Lung Cancer With MET Mutations
    • Aurora, Colorado
    • +3 more
    Jun 27, 2022

    Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

    Not yet recruiting
    • Ovarian Cancer
    • +4 more
    • (no location specified)
    Aug 8, 2022

    Acneiform Eruptions, Cancer, Treatment-Related Trial in Montreal (Doxycycline 100mg po once daily x 6 months, Isotretinoin 40 mg

    Recruiting
    • Acneiform Eruptions
    • Cancer, Treatment-Related
    • Doxycycline 100mg po once daily x 6 months
    • Isotretinoin 40 mg po once daily x 6 months
    • Montreal, Quebec, Canada
      Jewish General Hospital
    Aug 31, 2021

    Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)

    Recruiting
    • Protein Kinase Inhibitors
    • +3 more
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Nov 9, 2023

    Resistance-associated Mutations in Metastatic Lung Cancer

    Recruiting
    • Lung Cancer
    • Liquid biopsy
    • Monza, MB, Italy
      Fondazione IRCCS San Gerardo dei Tintori
    Oct 10, 2023

    Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
      • Moscow, Russian Federation
        Federal State Budgetary Institution National Medical Research Ce
      Mar 29, 2022